In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2337-2343

  Cushion, Melanie T ^a,b   Walzer, Peter D ^a,b   Ashbaugh, Alan ^a,b   Rebholz, Sandra ^a,b   Brubaker, Ronald ^c   Eynde, Jean Jacques Vanden ^d   Mayence, Annie ^d   Huang, Tien L ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHRIST HOSPITAL   (United States)

^d XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISBENZAMIDINE DERIVATIVE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL;

ALKANES; ANIMALS; ANTIFUNGAL AGENTS; BENZAMIDINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICE; MICE, INBRED C3H; PENTAMIDINE; PIPERAZINES; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS;

EID: 33745614936     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00126-06     Document Type: Article

References (46)

1. Armstrong, W., S. Meshnick, and P. Kazanjian. 2000. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes Infect. 2:61-67.
2. Assan, R., C. Perronne, D. Assan, L. Chotard, C. Mayaud, S. Matheron, and D. Zucman. 1995. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 18:47-55.
3. Beard, C. B., P. Roux, G. Nevez, P. M. Hauser, J. A. Kovacs, T. R. Unnasch, and B. Lundgren. 2004. Strain typing methods and molecular epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10:1729-1735.
4. Bell, C. A., C. C. Dykstra, N. A. Naiman, M. Cory, T. A. Fairley, and R. R. Tidwell. 1993. Structure-activity studies of dicationically substituted bis-benzamidazoles against Giardia lamblia: correlation of antigiardial activity with DNA-binding affinity and giardial topoisomerase II inhibition. Antimicrob. Agents Chemother. 37:2668-2773.
5. Bouchard, P., I. Caubarriere, D. Ganeval, P. Even, and R. Assan. 1978. Pentamidine, hypoglycemia, diabetes mellitus. J. Annu. Diabetol. Hotel Dieu 1978:273-279.
6. Bray, P. G., M. P. Barrett, S. A. Ward, and H. P. de Koning. 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 19:232-239.
7. Chen, F., and M. T. Cushion. 1994. Use of an ATP bioluminescence assay to evaluate viability of Pneumocystis carinii from rats. J. Clin. Microbiol. 32:2791-2800.
8. Cushion, M. T., F. Chen, and N. Kloepfer. 1997. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Antimicrob. Agents Chemother. 41:379-384.
9. Cushion, M. T., S. P. Keely, and J. R. Stringer. 2005. Validation of the name Pneumocystis wakefieldiae. Mycologia 97:268.
10. Cushion, M. T., and J. R. Stringer. 2004. Molecular and phenotypic description of Pneumocystis wakefieldiae sp. nov., a new species in rats. Mycologia 96:429-438.
11. Cushion, M. T., and P. D. Walzer. 2005. Development of candidate anti-Pneumocystis drugs: in vitro and in vivo approaches, p. 641-694. In P. D. Walzer and M. T. Cushion (ed.), Pneumocystis pneumonia. Marcel-Dekker, New York, N.Y.
12. Cushion, M. T., P. D. Walzer, M. S. Collins, S. Rebholz, J. J. Vanden Eynde, A. Mayence, and T. L. Huang. 2004. Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds. Antimicrob. Agents Chemother. 48:4209-4216.
13. Donkor, I. O., T. L. Huang, B. Tao, D. Rattendi, S. Lane, M. Vargas, B. Goldenberg, and C. J. Bacchi. 2003. Trypanocidal activity of conformationally restricted pentamidine congeners. J. Med. Chem. 46:1041-1048.
14. Dykstra, C. C., and R. R. Tidwell. 1991. Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules. J. Protozool. 38:78S-81S.
15. Fisk, D. T., S. Meshnick, and P. H. Kazanjian. 2003. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin. Infect. Dis. 36:70-78.
16. Frenkel, J. K. 1976. Pneumocystis jiroveci n. sp. from man: morphology, physiology, and immunology in relation to pathology. Natl. Cancer Inst. Monogr. 43:13-30.
17. Hall, J. E., J. E. Kerrigan, K. Ramachandran, B. C. Bender, J. P. Stanko, S. K. Jones, D. A. Patrick, and R. R. Tidwell. 1998. Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob. Agents Chemother. 42:666-674.
18. Hauser, P. M., D. S. Blanc, J. Bille, and P. Francioli. 1998. Typing methods to approach Pneumocystis carinii genetic heterogeneity. FEMS Immunol. Med. Microbiol. 22:27-35.
19. Huang, L., K. Crothers, C. Atzori, T. Benfield, R. Miller, M. Rabodonirina, and J. Helweg-Larsen. 2004. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg. Infect. Dis. 10:1721-1728.
20. Jones, S. K., J. E. Hall, M. A. Allen, S. D. Morrison, K. A. Ohemeng, V. V. Reddy, J. D. Geratz, and R. R. Tidwell. 1990. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 34:1026-1030.
21. Kazanjian, P., W. Armstrong, P. A. Hossler, C. H. Lee, L. Huang, C. B. Beard, J. Carter, L. Crane, J. Duchin, W. Burman, J. Richardson, and S. R. Meshnick. 2001. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J. Infect. Dis. 183:819-822.
22. Kazanjian, P., A. B. Locke, P. A. Hossler, B. R. Lane, M. S. Bartlett, J. W. Smith, M. Cannon, and S. R. Meshnick. 1998. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12:873-878.
23. Kazanjian, P. H., D. Fisk, W. Armstrong, Q. Shulin, H. Liwei, Z. Ke, and S. Meshnick. 2004. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. J. Infect. Dis. 189:1684-1687.
24. Keely, S. P., J. M. Fischer, M. T. Cushion, and J. R. Stringer. 2004. Phylogenetic identification of Pneumocystis murina sp. nov., a new species in laboratory mice. Microbiology 150:1153-1165.
25. Keely, S. P., J. M. Fischer, and J. R. Stringer. 2003. Evolution and speciation of Pneumocystis. J. Eukaryot. Microbiol. 50(Suppl.):624-626.
26. Lachaal, M., and R. C. Venuto. 1989. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am. J. Med. 87:260-263.
27. Liu, Y., R. R. Tidwell, and M. J. Leibowitz. 1994. Inhibition of in vitro splicing of a group I intron of Pneumocystis carinii. J. Eukaryot. Microbiol. 41:31-38.
28. Mayence, A., J. J. Vanden Eynde, F. M. Krogstad, D. J. Krogstad, M. T. Cushion, and T. L. Huang. 2004. Parallel solution-phase synthesis of conformationally restricted congeners of pentamidine and evaluation of their antiplasmodial activities. J. Med. Chem. 47:2700-2705.
29. Mayence, A., J. J. Vanden Eynde, L. LeCour, Jr., L. A. Walker, B. L. Tekwani, and T. L. Huang. 2004. Piperazine-linked bisbenzamidines: a novel class of antileishmanial agents. Eur. J. Med. Chem. 39:547-553.
30. Morris, A., J. D. Lundgren, H. Masur, P. D. Walzer, D. L. Hanson, T. Frederick, L. Huang, C. B. Beard, and J. E. Kaplan. 2004. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10:1713-1720.
31. Queener, S. F. 1995. New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J. Med. Chem. 38:4739-4759.
32. Redhead, S. A., M. T. Cushion, J. K. Frenkel, and J. R. Stringer. 2006. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J. Eukaryot. Microbiol. 53:2-11.
33. Tao, B., T. L. Huang, Q. Zhang, L. Jackson, S. F. Queener, and I. O. Donkor. 1999. Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine. Eur. J. Med. Chem. 34:531-538.
34. Tidwell, R. R., S. K. Jones, J. D. Geratz, K. A. Ohemeng, C. A. Bell, B. J. Berger, and J. E. Hall. 1990. Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia. Ann. N. Y. Acad. Sci. 616:421-441.
35. Tidwell, R. R., S. K. Jones, J. D. Geratz, K. A. Ohemeng, M. Cory, and J. E. Hall. 1990. Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J. Med. Chem. 33:1252-1257.
36. Tidwell, R. R., S. G. Kilgore, K. A. Ohemeng, J. D. Geratz, and J. E. Hall. 1989. Treatment of experimental Pneumocystis carinii pneumonia with analogs of pentamidine. J. Protozool. 36:74S-76S.
37. Vanden Eynde, J. J., A. Mayence, T. L. Huang, M. S. Collins, S. Rebholz, P. D. Walzer, and M. T. Cushion. 2004. Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia. Bioorg. Med. Chem. Lett. 14:4545-4548.
38. Vanden Eynde, J. J., A. Mayence, L. LeCour, Jr., and T. L. Huang. 2003. Synthesis, antituberculosis activity, and DNA binding affinity of a highly diverse library of 1,4-diarylpiperazines. Med. Chem. Res. 12:401-414.
39. Walzer, P. D. 1994. Development of new anti-Pneumocystis carinii drugs: cumulative experience at a single institution, p. 511-544. In P. D. Walzer (ed.), Pneumocystis carinii pneumonia. Marcel-Dekker, Inc., New York, N.Y.
40. Walzer, P. D., and A. Ashbaugh. 2002. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 46:514-516.
41. Walzer, P. D., A. Ashbaugh, M. Collins, and M. T. Cushion. 2001. In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii. Antimicrob. Agents Chemother. 45:3234-3237.
42. Walzer, P. D., J. Foy, J. Runck, P. Steele, M. White, R. S. Klein, B. A. Otter, and R. J. Sundberg. 1994. Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats. Antimicrob. Agents Chemother. 38:2572-2576.
43. Walzer, P. D., J. Foy, P. Steele, and M. White. 1992. Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob. Agents Chemother. 36:1943-1950.
44. Walzer, P. D., C. K. Kim, J. Foy, M. J. Linke, and M. T. Cushion. 1988. Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 32:896-905.
45. Walzer, P. D., J. Runck, P. Steele, M. White, M. J. Linke, and C. L. Sidman. 1997. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Antimicrob. Agents Chemother. 41:251-258.
46. Zhang, Y., Z. Li, D. S. Pilch, and M. J. Leibowitz. 2002. Pentamidine inhibits catalytic activity group I intron Ca.LSU by altering RNA folding. Nucleic Acids Res. 30:2961-2971.